Ergänzende bilanzierte Diät mit essenziellen Aminosäuren bei chronischen Krankheiten und im fortgeschrittenen Alter

Zusammenfassung

Die Entstehung von Sarkopenie und Kachexie sind wesentlich durch den Proteinmetabolismus der Muskulatur determiniert. Hierbei ist eine Vielzahl pathophysiologischer Mechanismen mit einer Dysbalance zwischen anabolen und katabolen Faktoren involviert. Im Gegensatz zur Kachexie ist die Sarkopenie im Regelfall nicht mit einem Gewichtsverlust assoziiert, wohl aber mit funktioneller Einbuße und deren klinischen Konsequenzen. In den vergangenen Jahren wurde eine große Zahl von Studien vorgelegt, die den Wert einer ergänzenden bilanzierten Diät mit essenziellen Aminosäuren bei Sarkopenie und bei Erkrankungen, die häufig mit der Entwicklung einer Kachexie assoziiert sind, belegen. Hierzu gehören Diabetes mellitus, chronische Herz- und Niereninsuffizienz, chronisch-obstruktive Lungenerkrankung und Tumorerkrankungen. Nach einem Überblick über die pathophysiologischen Hintergründe des Muskelproteinstoffwechsels und der klinischen Diskussion der Sarkopenie und Kachexie beschreibt dieser Artikel die Studienlage zur ergänzenden bilanzierten Diät mit essenziellen Aminosäuren bei diesen Erkrankungen.

Abstract

Muscle protein metabolism is the main determinant in the development of both sarcopenia and cachexia. A vast array of pathophysiological mechanisms is involved in the dysbalance between anabolic and catabolic factors. Unlike cachexia, sarcopenia is not usually associated with weight loss. However, one of the prominent features of sarcopenia is the development of functional impairment and its clinical consequences. Over the last several years, a large number of studies has been published that buttress the value of essential amino acids as a nutritional supplement in sarcopenia and in chronic illnesses that are frequently associated with the development of cachexia. Such illnesses include diabetes mellitus, chronic heart and chronic renal failure, chronic obstructive pulmonary disease and malignant diseases. This article reviews the pathophysiological background of muscle protein metabolism as well as sarcopenia and cachexia as clinical entities. Moreover, this article provides an overview of studies that used essential amino acids as a nutritional supplement in the aforementioned illnesses.

Sarkopenie - Kachexie - essenzielle Aminosäuren - Proteinstoffwechsel - Muskel - chronische Krankheit

sarcopenia - cachexia - essentiell amino acids - protein metabolism - muscle - chronic illness

• 1 Doehner W, Anker S D. Cardiac cachexia in early literature: a review of research prior to Medline.  Int J Cardiol. 2002;  85 7-14
• 2 von Haehling S, Genth-Zotz S, Anker S D. et al . Cachexia: a therapeutic approach beyond cytokine antagonism.  Int J Cardiol. 2002;  85 173-183
• 3 Kamel H K. Sarcopenia and aging.  Nutr Rev. 2003;  61 157-167
• 4 Lang T, Streeper T, Cawthon P. et al . Sarcopenia: etiology, clinical consequences, intervention, and assessment.  Osteoporos Int. 2010 (in Druck);  , DOI: DOI: 10.1007/s00198-009-1059-y
• 5 Joseph C, Kenny A M, Taxel P. et al . Role of endocrine-immune dysregulation in osteoporosis, sarcopenia, frailty and fracture risk.  Mol Aspects Med. 2005;  26 181-201
• 6 Muscaritoli M, Anker S D, Argilés J. et al . Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) „cachexia-anorexia in chronic wasting diseases” and „nutrition in geriatrics”.  Clin Nutr. 2010 (in Druck);  , DOI: DOI: 10.1016/j.clnu.2009.12.004
• 7 Doherty T J. Invited review: Aging and sarcopenia.  J Appl Physiol. 2003;  95 1717-1727
• 8 Evans W J, Morley J E, Argilés J. et al . Cachexia: a new definition.  Clin Nutr. 2008;  27 793-799
• 9 Rosenberg I H. Sarcopenia: origins and clinical relevance.  J Nutr. 1997;  127 (5 Suppl.) 990S-991S
• 10 Cruz-Jentoft A J, Landi F, Topinková E. et al . Understanding sarcopenia as a geriatric syndrome.  Curr Opin Clin Nutr Metab Care. 2010;  13 1-7
• 11 Frontera W R, Meredith C N, O’Reilly K P. et al . Strength conditioning in older men: skeletal muscle hypertrophy and improved function.  J Appl Physiol. 1988;  64 1038-1044
• 12 Charette S L, McEvoy L, Pyka G. et al . Muscle hypertrophy response to resistance training in older women.  J Appl Physiol. 1991;  70 1912-1916
• 13 Buse M G, Reid S S. Leucine. A possible regulator of protein turnover in muscle.  J Clin Invest. 1975;  56 1250-1261
• 14 Stein T P, Donaldson M R, Leskiw M J. et al . Branched-chain amino acid supplementation during bed rest: effect on recovery.  J Appl Physiol. 2003;  94 1345-1352
• 15 Chen Scarabelli C, McCauley R B, Yuan Z. et al . Oral administration of amino acidic supplements improves protein and energy profiles in skeletal muscle of aged rats: elongation of functional performance and acceleration of mitochondrial recovery in adenosine triphosphate after exhaustive exertion.  Am J Cardiol. 2008;  101 42E-48E
• 16 Pansarasa O, Flati V, Corsetti G. et al . Oral amino acid supplementation counteracts age-induced sarcopenia in elderly rats.  Am J Cardiol. 2008;  101 35E-41E
• 17 Dorofeyeva E E, Dorofeyev A E. Biochemical and heart adaptations to physical training and supplementation with amino acids.  J Strength Cond Res. 2004;  18 738-740
• 18 Solerte S B, Gazzaruso C, Bonacasa R. et al . Nutritional supplements with oral amino acid mixtures increases whole-body lean mass and insulin sensitivity in elderly subjects with sarcopenia.  Am J Cardiol. 2008;  101 69E-77E
• 19 Scognamiglio R, Piccolotto R, Negut C. et al . Oral amino acids in elderly subjects: effect on myocardial function and walking capacity.  Gerontology. 2005;  51 302-308
• 20 Tahiliani A G, McNeill J H. Diabetes-induced abnormalities in the myocardium.  Life Sci. 1986;  38 959-974
• 21 Avogaro A, Nosadini R, Doria A. et al . Myocardial metabolism in insulin-deficient diabetic humans without coronary artery disease.  Am J Physiol. 1990;  258 E606-E618
• 22 Barrett E J, Schwartz R G, Young L H. et al . Effect of chronic diabetes on myocardial fuel metabolism and insulin sensitivity.  Diabetes. 1988;  37 943-948
• 23 Scognamiglio R, Negut C, Piccolotto R. et al . Effects of oral amino acid supplementation on myocardial function in patients with type 2 diabetes mellitus.  Am Heart J. 2004;  147 1106-1112
• 24 Scognamiglio R, Negut C, Palisi M. et al . Effects of oral amino acid supplements on cardiac function and remodeling in patients with type 2 diabetes with mild-to-moderate left ventricular dysfunction.  Am J Cardiol. 2008;  101 111E-115E
• 25 Solerte S B, Gazzaruso C, Schifino N. et al . Metabolic effects of orally administered amino acid mixture in elderly subjects with poorly controlled type 2 diabetes mellitus.  Am J Cardiol. 2004;  93 23A-29A
• 26 Solerte S B, Fioravanti M, Locatelli E. et al . Improvement of blood glucose control and insulin sensitivity during a long-term (60 weeks) randomized study with amino acid dietary supplements in elderly subjects with type 2 diabetes mellitus.  Am J Cardiol. 2008;  101 82E-88E
• 27 Pellegrino M A, Patrini C, Pasini E. et al . Amino acid supplementation counteracts metabolic and functional damage in the diabetic rat heart.  Am J Cardiol. 2008;  101 49E-56E
• 28 Brocca L, D’Antona G, Bachi A. et al . Amino acid supplements improve native antioxidant enzyme expression in the skeletal muscle of diabetic mice.  Am J Cardiol. 2008;  101 57E-62E
• 29 Manzella D, Grella R, Esposito K. et al . Oral amino acid administration decreases oxidative stress and improves brachial reactivity in elderly individuals.  Am J Hypertens. 2005;  18 858-863
• 30 Witte K, Nikitin N P, Parker A C. et al . The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure.  Eur Heart J. 2005;  26 2238-2244
• 31 von Haehling S, Lainscak M, Springer J. et al . Cardiac cachexia: a systematic overview.  Pharmacol Ther. 2009;  121 227-252
• 32 Anker S D, Ponikowski P, Varney S. et al . Wasting as independent risk factor for mortality in chronic heart failure.  Lancet. 1997;  349 1050-1053
• 33 von Haehling S, Schefold J C, Lainscak M. et al . Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders.  Heart Fail Clin. 2009;  5 549-560
• 34 Aquilani R, Viglio S, Iadarola P. et al . Oral amino acid supplements improve exercise capacities in elderly patients with chronic heart failure.  Am J Cardiol. 2008;  101 104E-110E
• 35 Macchi A, Franzoni I, Buzzetti F. et al . The role of essential amino acid supplementation in chronic heart failure.  Eur Heart J. 2009;  30 (Suppl.) 869 (Abstract)
• 36 Aquilani R, Opasich C, Gualco A. et al . Adequate energy-protein intake is not enough to improve nutritional and metabolic status in muscle-depleted patients with chronic heart failure.  Eur J Heart Fail. 2008;  10 1127-1135
• 37 Abboud H, Henrich W L. Clinical practice. Stage IV chronic kidney disease.  N Engl J Med. 2010;  362 56-65
• 38 Caria S, Secci R, Bolasco P. Vantaggi di una nuova miscela con apporto aminoacidico bilanciato sullo stato nutrizionale del paziente in dialisi.  G Ital Nefrol. 2009;  26 S94 (Abstract)
• 39 Pfeffer M A, Burdmann E A, Chen C Y. et al, TREAT Investigators . A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.  N Engl J Med. 2009;  361 2019-2032
• 40 Apolone G, Tafuri G, Trotta F. et al . A new anti-cancer drug in the market: good news for investors or for patients?.  Eur J Cancer. 2008;  44 1786-1788
• 41 Schulz C, Emslander H P, Riedel M. Risk assessment of patients before lung surgery.  Chirurgie. 1999;  70 664-673
• 42 O’Leary N, Murphy N F, O’Loughlin C. et al . A comparative study of the palliative care needs of heart failure and cancer patients.  Eur J Heart Fail. 2009;  11 406-412
• 43 Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients.  Support Care Cancer. 2000;  8 175-179
• 44 Baracos V E, Reiman T, Mourtzakis M. et al . Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis.  Am J Clin Nutr. 2010 (in Druck);  , DOI: DOI: 10.3945/ajcn.2010.28608C
• 45 Prado C M, Lieffers J R, McCargar L J. et al . Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study.  Lancet Oncol. 2008;  9 629-635
• 46 Roubenoff R. Excess baggage: sarcopenia, obesity, and cancer outcomes.  Lancet Oncol. 2008;  9 605-607
• 47 Madeddu C, Maccio A, Astara G. et al . Open phase II study on efficacy and safety of an oral amino acid functional cluster formation in cancer cachexia.  Mediteri J Nutr Metab. 2010 (in Druck); 
• 48 Tan B H, Fearon K C. Cachexia: prevalence and impact in medicine.  Curr Opin Clin Nutr Metab Care. 2008;  11 400-407
• 49 Koehler F, Doehner W, Hoernig S. et al . Anorexia in chronic obstructive pulmonary disease – association to cachexia and hormonal derangement.  Int J Cardiol. 2007;  119 83-89
• 50 Baldi S, Aquilani R, Poggi P. et al . Essential amino acid supplementation in depleted copd: an effective intervention for fat free mass maintenance and improvement of physical performance.  Eur Med Phys. 2008;  44 (Suppl.) 1-4
• 51 Gariballa S E, Parker S G, Taub N. et al . A randomized, controlled, a single-blind trial of nutritional supplementation after acute stroke.  JPEN J Parenter Enteral Nutr. 1998;  22 315-319
• 52 Aquilani R, Scocchi M, Iadarola P. et al . Protein supplementation may enhance the spontaneous recovery of neurological alterations in patients with ischaemic stroke.  Clin Rehabil. 2008;  22 1042-1050